Cell News and Research

RSS

Susan Mallery finds breakthrough treatment for oral cancer

Dr. Susan Mallery, a professor in the College of Dentistry at The Ohio State University and Oral Pathology Consultant at the Ohio State University and James Cancer hospitals, has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer.

30 Jan 2012

DNA sequencing for difficult diagnoses of mitochondrial diseases may hit clinics soon

Identifying complete DNA sequences could identify difficult-to-diagnose diseases in humans. This concept is being used for the first time in a clinic. MitoExome sequencing uses new technologies known as next-generation sequencing (NGS) to decode all of the genes associated with mitochondria. Mitochondria are a capsule shaped organelle present within the cell. It is the powerhouse of the cell and its genes are inherited completely from the mother.

29 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

Study shows grape seed extract kills head and neck squamous cell carcinoma cells

Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million.

27 Jan 2012

Positive results from cisplatin plus radiation therapy trial on head and neck cancer

A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to show positive results 10 years post-treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

27 Jan 2012

Cancer Research UK opens first AT9283 trial to treat childhood leukaemia

Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.

27 Jan 2012

Researchers discover new gene linked to MLCRD

Researchers have found a new gene that, when mutated, can lead to lymphoedema (swollen limbs) as part of a rare disorder that can also cause problems with eye and brain development. This is the fourth lymphoedema-related gene found by the same researchers in three years, and the first linked to the eyes and brain. They say it could lead to better diagnosis and treatment for lymphoedema, an area that has been poorly understood previously.

27 Jan 2012

Rotational motion plays a critical role in ability of breast cells to form acini

In a study that holds major implications for breast cancer research as well as basic cell biology, scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory have discovered a rotational motion that plays a critical role in the ability of breast cells to form the spherical structures in the mammary gland known as acini.

27 Jan 2012

Renowned publisher introduces Cell Reports

Cell Press reinforces its commitment to provide a broad range of publishing options for the life sciences community with the inaugural issue of a new open-access journal: Cell Reports.

27 Jan 2012

Scientists connect two signature characteristics of pancreatic cancer

Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.

27 Jan 2012

Strong link between high HuR protein levels and malignancy of HCC

Researchers at CIC Biogune, the Cooperative Centre for Research into Biosciences and led by Dr. Maria Luz Martinez Chantar, have found a strong relationship between high levels of Hu antigen R (HuR) protein and the malignancy of Hepatocellular Carcinoma, through a novel molecular process in the investigation of this pathology and known as neddylation.

27 Jan 2012

Weill Cornell establishes Office of Faculty Development

Weill Cornell Medical College has announced the establishment of the Office of Faculty Development dedicated to assisting its physicians, researchers and educators in achieving academic success at each stage of their careers, with targeted activities that focus on the needs of junior, mid-career and senior faculty.

27 Jan 2012

New links between leukemia cells and osteoblasts

University of Rochester Medical Center researchers have discovered new links between leukemia cells and cells involved in bone formation, offering a fresh perspective on how the blood cancer progresses and raising the possibility that therapies for bone disorders could help in the treatment of leukemia.

27 Jan 2012

Amgen enters definitive merger agreement to acquire Micromet

Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

27 Jan 2012

New technique to overcome genetic oddity of P. falciparum

The parasite that causes malaria is a genetic outlier, which has prevented scientists from discovering the functions of most of its genes. Researchers at National Jewish Health and Yale University School of Medicine have devised a technique to overcome the genetic oddity of Plasmodium falciparum, the major cause of human malaria.

27 Jan 2012

Routine PET/CT scan use in head and neck cancer patients can detect local recurrences

Routine use of positron emission tomography/computed tomography (PET/CT) scans in head and neck cancer patient follow-up can detect local recurrences before they become clinically apparent and may improve the outcome of subsequent salvage therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

27 Jan 2012

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis.

27 Jan 2012

Celgene signs definitive merger agreement to acquire Avila

Celgene Corporation and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.

26 Jan 2012

Breakthroughs in Alzheimer’s disease research

Researchers are closer to understanding Alzheimer’s disease using a new stem cell technique. They have successfully replicated Alzheimer’s disease neurons with stem cells for the first time.

26 Jan 2012